In this article, Professor Orentlicher explores free speech and federalism issues arising from FDA regulation of off-label uses and off-label marketing of drugs. In light of the FDA's desire to respect state government authority, together with other considerations discussed in this article, he argues for the rejection of the analysis of the Caronia court and to give the FDA significant leeway in its regulation of off-label marketing.
50 Wash. U. J. L. & Pol'y 89 (2016).
Orentlicher, David, "Off-Label Drug Marketing, the First Amendment, and Federalism" (2016). Scholarly Works. 1037.